source
- Gilead reports modest sales rise but analysts question future growth beyond HIV drugsGilead's second‑quarter results showed total product revenue of $7.6 billion, up 8% year‑over‑year. The company's two leading HIV treatments, Biktarvy and Descovy, together generated about $5.7 bi…
- AstraZeneca and Bristol Myers Squibb abandon merger talksReuters reported that AstraZeneca and Bristol Myers Squibb have ended discussions about a possible merger and will not pursue a deal. The collapse of the talks removes a potential consolidation th…